Psychopharmacological Treatments for Mental Disorders in Patients with Neuromuscular Diseases: A Scoping Review
Mental disorders are observed in neuromuscular diseases, especially now that patients are living longer. Psychiatric symptoms may be severe and psychopharmacological treatments may be required. However, very little is known about pharmacotherapy in these conditions. We aimed to summarize the current...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-01-01
|
| Series: | Brain Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-3425/12/2/176 |
| _version_ | 1797482208381894656 |
|---|---|
| author | Chiara Brusa Giulio Gadaleta Rossella D’Alessandro Guido Urbano Martina Vacchetti Chiara Davico Benedetto Vitiello Federica S. Ricci Tiziana E. Mongini |
| author_facet | Chiara Brusa Giulio Gadaleta Rossella D’Alessandro Guido Urbano Martina Vacchetti Chiara Davico Benedetto Vitiello Federica S. Ricci Tiziana E. Mongini |
| author_sort | Chiara Brusa |
| collection | DOAJ |
| description | Mental disorders are observed in neuromuscular diseases, especially now that patients are living longer. Psychiatric symptoms may be severe and psychopharmacological treatments may be required. However, very little is known about pharmacotherapy in these conditions. We aimed to summarize the current knowledge on the use of psychopharmacological treatments for mental disorders in patients living with a neuromuscular disease. A scoping review was performed using the methodology of the Joanna Briggs Institute. Four databases were searched from January 2000 to July 2021. Articles were screened based on titles and abstracts. Full-text papers published in peer-reviewed journals in English were selected. Twenty-six articles met eligibility criteria, all being case reports/series focusing on the psychopharmacological control of psychiatric symptoms for the following conditions: myasthenia gravis (<i>n</i> = 11), Duchenne (<i>n</i> = 5) and Becker (<i>n</i> = 3) muscular dystrophy, mitochondrial disorders (<i>n</i> = 3), glycogen storage disease (<i>n</i> = 1), myotonic dystrophy (<i>n</i> = 1), hyperkalemic periodic paralysis (<i>n</i> = 1), and congenital myasthenic syndrome (<i>n</i> = 1). None of the articles provided details on the decision-making process to choose a specific drug/regimen or on follow-up strategies to monitor safety and efficacy. Larger studies showing real-world data would be required to guide consensus-based recommendations, thus improving current standards of care and, ultimately, the quality of life of patients and their families. |
| first_indexed | 2024-03-09T22:28:00Z |
| format | Article |
| id | doaj.art-761e82a98812470da9901955fe93034d |
| institution | Directory Open Access Journal |
| issn | 2076-3425 |
| language | English |
| last_indexed | 2024-03-09T22:28:00Z |
| publishDate | 2022-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Brain Sciences |
| spelling | doaj.art-761e82a98812470da9901955fe93034d2023-11-23T19:02:43ZengMDPI AGBrain Sciences2076-34252022-01-0112217610.3390/brainsci12020176Psychopharmacological Treatments for Mental Disorders in Patients with Neuromuscular Diseases: A Scoping ReviewChiara Brusa0Giulio Gadaleta1Rossella D’Alessandro2Guido Urbano3Martina Vacchetti4Chiara Davico5Benedetto Vitiello6Federica S. Ricci7Tiziana E. Mongini8Section of Child and Adolescent Neuropsychiatry, Department of Public Health and Pediatric Sciences, University of Turin, 10126 Turin, ItalyNeuromuscular Unit, Department of Neurosciences “Rita Levi Montalcini”, University of Turin, 10126 Turin, ItalySection of Child and Adolescent Neuropsychiatry, Department of Public Health and Pediatric Sciences, University of Turin, 10126 Turin, ItalyNeuromuscular Unit, Department of Neurosciences “Rita Levi Montalcini”, University of Turin, 10126 Turin, ItalySection of Child and Adolescent Neuropsychiatry, Department of Public Health and Pediatric Sciences, University of Turin, 10126 Turin, ItalySection of Child and Adolescent Neuropsychiatry, Department of Public Health and Pediatric Sciences, University of Turin, 10126 Turin, ItalySection of Child and Adolescent Neuropsychiatry, Department of Public Health and Pediatric Sciences, University of Turin, 10126 Turin, ItalySection of Child and Adolescent Neuropsychiatry, Department of Public Health and Pediatric Sciences, University of Turin, 10126 Turin, ItalyNeuromuscular Unit, Department of Neurosciences “Rita Levi Montalcini”, University of Turin, 10126 Turin, ItalyMental disorders are observed in neuromuscular diseases, especially now that patients are living longer. Psychiatric symptoms may be severe and psychopharmacological treatments may be required. However, very little is known about pharmacotherapy in these conditions. We aimed to summarize the current knowledge on the use of psychopharmacological treatments for mental disorders in patients living with a neuromuscular disease. A scoping review was performed using the methodology of the Joanna Briggs Institute. Four databases were searched from January 2000 to July 2021. Articles were screened based on titles and abstracts. Full-text papers published in peer-reviewed journals in English were selected. Twenty-six articles met eligibility criteria, all being case reports/series focusing on the psychopharmacological control of psychiatric symptoms for the following conditions: myasthenia gravis (<i>n</i> = 11), Duchenne (<i>n</i> = 5) and Becker (<i>n</i> = 3) muscular dystrophy, mitochondrial disorders (<i>n</i> = 3), glycogen storage disease (<i>n</i> = 1), myotonic dystrophy (<i>n</i> = 1), hyperkalemic periodic paralysis (<i>n</i> = 1), and congenital myasthenic syndrome (<i>n</i> = 1). None of the articles provided details on the decision-making process to choose a specific drug/regimen or on follow-up strategies to monitor safety and efficacy. Larger studies showing real-world data would be required to guide consensus-based recommendations, thus improving current standards of care and, ultimately, the quality of life of patients and their families.https://www.mdpi.com/2076-3425/12/2/176neuromuscular diseasesmental disorderspsychiatric symptomspsychopharmacological treatments |
| spellingShingle | Chiara Brusa Giulio Gadaleta Rossella D’Alessandro Guido Urbano Martina Vacchetti Chiara Davico Benedetto Vitiello Federica S. Ricci Tiziana E. Mongini Psychopharmacological Treatments for Mental Disorders in Patients with Neuromuscular Diseases: A Scoping Review Brain Sciences neuromuscular diseases mental disorders psychiatric symptoms psychopharmacological treatments |
| title | Psychopharmacological Treatments for Mental Disorders in Patients with Neuromuscular Diseases: A Scoping Review |
| title_full | Psychopharmacological Treatments for Mental Disorders in Patients with Neuromuscular Diseases: A Scoping Review |
| title_fullStr | Psychopharmacological Treatments for Mental Disorders in Patients with Neuromuscular Diseases: A Scoping Review |
| title_full_unstemmed | Psychopharmacological Treatments for Mental Disorders in Patients with Neuromuscular Diseases: A Scoping Review |
| title_short | Psychopharmacological Treatments for Mental Disorders in Patients with Neuromuscular Diseases: A Scoping Review |
| title_sort | psychopharmacological treatments for mental disorders in patients with neuromuscular diseases a scoping review |
| topic | neuromuscular diseases mental disorders psychiatric symptoms psychopharmacological treatments |
| url | https://www.mdpi.com/2076-3425/12/2/176 |
| work_keys_str_mv | AT chiarabrusa psychopharmacologicaltreatmentsformentaldisordersinpatientswithneuromusculardiseasesascopingreview AT giuliogadaleta psychopharmacologicaltreatmentsformentaldisordersinpatientswithneuromusculardiseasesascopingreview AT rosselladalessandro psychopharmacologicaltreatmentsformentaldisordersinpatientswithneuromusculardiseasesascopingreview AT guidourbano psychopharmacologicaltreatmentsformentaldisordersinpatientswithneuromusculardiseasesascopingreview AT martinavacchetti psychopharmacologicaltreatmentsformentaldisordersinpatientswithneuromusculardiseasesascopingreview AT chiaradavico psychopharmacologicaltreatmentsformentaldisordersinpatientswithneuromusculardiseasesascopingreview AT benedettovitiello psychopharmacologicaltreatmentsformentaldisordersinpatientswithneuromusculardiseasesascopingreview AT federicasricci psychopharmacologicaltreatmentsformentaldisordersinpatientswithneuromusculardiseasesascopingreview AT tizianaemongini psychopharmacologicaltreatmentsformentaldisordersinpatientswithneuromusculardiseasesascopingreview |